Skip to main content

Drug Interactions between belumosudil and Prilosec OTC

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

omeprazole belumosudil

Applies to: Prilosec OTC (omeprazole) and belumosudil

ADJUST DOSE: Coadministration with proton pump inhibitors (PPIs) or potassium-competitive acid blockers (PCABs) may decrease systemic exposure to belumosudil. The mechanism of interaction has not been established. Concomitant use of the PPI rabeprazole decreased belumosudil peak plasma concentration (Cmax) and systemic exposure (AUC) by 87% and 80%, respectively, while coadministration of omeprazole decreased belumosudil Cmax and AUC by 68% and 47%, respectively, in healthy subjects. Reduced efficacy of belumosudil may occur.

MANAGEMENT: When coadministered with PPIs or PCABs, the dose of belumosudil should be increased to 200 mg twice daily.

References (2)
  1. (2021) "Product Information. Rezurock (belumosudil)." Kadmon Pharmaceuticals
  2. (2024) "Product Information. Rezurock (belumosudil)." Sanofi

Drug and food interactions

Moderate

belumosudil food

Applies to: belumosudil

ADJUST DOSING INTERVAL: Administration with food increases the oral bioavailability of belumosudil. The mechanism has not been described. Administration of belumosudil (200 mg single oral dose) in healthy subjects, with a fatty and calorie-rich meal (approximately half of the calories were contained in the fat) increased the mean belumosudil peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 120% and 100%, respectively, compared to administration under fasting conditions. The time to reach peak concentration (Tmax) was delayed by 30 minutes. Administration of oral belumosudil 200 mg once daily with food in patients with chronic graft-versus-host disease (chronic GVHD) lead to steady-state concentrations of the drug with an accumulation ration of 1.4.

MANAGEMENT: To ensure maximal oral absorption, belumosudil should be administered with a meal, every day at the same time.

References (2)
  1. (2024) "Product Information. Rezurock (belumosudil)." Sanofi
  2. (2024) "Product Information. Rezurock (belumosudil)." Kadmon Pharmaceuticals, 11/2023

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer